A Phase 3 interventional study of OPA-15406 in Atopic Dermatitis (AD), sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 3 Months to 2 Years. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing difamilast in Dermatitis, Atopic — 2 open to participants now, 2 under way, 2 of them phase 3. difamilast · Dermatitis, Atopic.
Among the 16 studies testing difamilast in Dermatitis, Atopic, this one is the 14th largest by enrollment, is one of 3 that started in 2022, is one of 10 in phase 3, and was the 10th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 16 studies testing difamilast in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 15–70
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 3 mo–14 yrs
By country, each count listing its studies:
difamilast: first FDA approval 2026 (ADQUEY). What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 3 Months to 2 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2022.
This study's enrollment of 41 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 177 across the 16 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 16 have an industry lead sponsor. The 5 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
13 studies in Dermatitis, Atopic by Otsuka Holdings Co., Ltd.: 2 open now, 2 under way, 2 of them phase 3. Of 11 finished, 8 (73%) have results posted.
Among the 13 studies in Dermatitis, Atopic by Otsuka Holdings Co., Ltd., this one is the 12th largest by enrollment, is the only one that started in 2022, is one of 8 in phase 3, and was the 9th registered.
Otsuka Holdings Co., Ltd.’s Dermatitis, Atopic studies by the year they started, since 2012.
2 of the studies testing difamilast in Dermatitis, Atopic that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173478Phase 3Otsuka Pharmaceutical Co., Ltd.A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis | 2026-12 |
| NCT07184645Phase 3Otsuka Pharmaceutical Co., Ltd.A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies testing difamilast in Dermatitis, Atopic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 13 in Dermatitis, Atopic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate the efficacy of 0.3% OPA-15406 ointment when administered twice daily for 4 weeks in infants younger than 2 years of age with Atopic Dermatitis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-Subjects who have an AD or contact dermatitis flare-up defined as a rapid intensification of AD, within 28 days prior to the baseline examination
Drug: OPA-15406
0.3% or 1% ointment, topical, twice daily, for 52 weeks
Also known as: difamilast
Success Rate in IGA (Percentage of Subjects With an IGA Score of 0 or 1 With Improvement by at Least 2 Grades)
The investigator or sub investigator assessed the skin symptoms using IGA (Investigator's Global Assessment). The investigator or sub investigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week 4. Incidence of success in IGA was defined as the rate of subjects whose IGA score is 0 (clear) or 1 (almost clear) and had improved by at least 2 grades (responders) from baseline.
Time frame: Week 4
Response Rate in Eczema Area and Severity Index (EASI) 75 (Improvement of ≥75% in EASI)
Response (improvement) in EASI 75 was defined as a decrease by ≥75% in the percent change from baseline in the total score of EASI.
Time frame: Week4
| Milestone | 0.3% OPA-15406 | 1% OPA-15406 |
|---|---|---|
| Started | 12 | 29 |
| Completed | 11 | 25 |
| Not completed | 1 | 4 |
| Withdrew: Study treatment terminated by parent/guardian | 1 | 3 |
| Withdrew: Adverse event | 0 | 1 |
The investigator or sub investigator assessed the skin symptoms using IGA (Investigator's Global Assessment). The investigator or sub investigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week 4. Incidence of success in IGA was defined as the rate of subjects whose IGA score is 0 (clear) or 1 (almost clear) and had improved by at least 2 grades (responders) from baseline.
| Percentage of perticipants | 0.3% OPA-15406 |
|---|---|
| Success Rate in IGA (Percentage of Subjects With an IGA Score of 0 or 1 With Improvement by at Least 2 Grades) | 56.10 (39.75 to 71.53) |
Response (improvement) in EASI 75 was defined as a decrease by ≥75% in the percent change from baseline in the total score of EASI.
| Percentage of perticipants | 0.3% OPA-15406 |
|---|---|
| Response Rate in Eczema Area and Severity Index (EASI) 75 (Improvement of ≥75% in EASI) | 82.93 (67.94 to 92.85) |
Collected over Adverse event collection begins after a legal guardian signs the ICF, and continues until the completion of the 52-week follow-up examination (or the final observation day).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.3% OPA-15406 | 0/41 (0%) | 1/41 (2.4%) | 24/41 (58.5%) |
| 1% OPA-15406 | 0/29 (0%) | 1/29 (3.4%) | 29/29 (100%) |
| Event | 0.3% OPA-15406 | 1% OPA-15406 |
|---|---|---|
| Kawasaki's diseaseVascular disorders | 0/41 | 1/29 |
| Respiratory syncytial virus infectionInfections and infestations | 1/41 | 0/29 |
| Event | 0.3% OPA-15406 | 1% OPA-15406 |
|---|---|---|
| NasopharyngitisInfections and infestations | 18/41 | 24/29 |
| GastroenteritisInfections and infestations | 4/41 | 16/29 |
| Dermatitis diaperSkin and subcutaneous tissue disorders | 0/41 | 10/29 |
| Otitis media acuteInfections and infestations | 0/41 | 8/29 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 8/41 | 8/29 |
| COVID-19Infections and infestations | 4/41 | 7/29 |
| Conjunctivitis bacterialInfections and infestations | 0/41 | 6/29 |
| FolliculitisInfections and infestations | 0/41 | 5/29 |
| Hand-foot-and-mouth diseaseInfections and infestations | 0/41 | 5/29 |
| ConstipationGastrointestinal disorders | 0/41 | 4/29 |
| Age, Continuous(Months) | 0.3% OPA-15406 | 1% OPA-15406 | Total |
|---|---|---|---|
| Mean | 7.9 ± 3.9 | 10.8 ± 5.4 | 10.0 ± 5.1 |
| Age, Customized(Participants) | 0.3% OPA-15406 | 1% OPA-15406 | Total |
|---|---|---|---|
| Age Group — <12 months | 10 | 18 | 28 |
| Age Group — >=12 months | 2 | 11 | 13 |
| Sex: Female, Male(Participants) | 0.3% OPA-15406 | 1% OPA-15406 | Total |
|---|---|---|---|
| Female | 5 | 10 | 15 |
| Male | 7 | 19 | 26 |
| Race/Ethnicity, Customized(Participants) | 0.3% OPA-15406 | 1% OPA-15406 | Total |
|---|---|---|---|
| Japanese | 12 | 29 | 41 |
| Region of Enrollment(participants) | 0.3% OPA-15406 | 1% OPA-15406 | Total |
|---|---|---|---|
| Japan | 12 | 29 | 41 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.
Ran from May 2022 to primary completion in Dec 2022, 7 months.
Results were first posted in Mar 2025, 2 years 3 months after primary completion.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 7 months is below that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Difamilast
Otsuka Pharmaceutical Co., Ltd. →